Active, not recruitingPhase 3NCT04919226
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
Studying Functioning neuroendocrine tumor of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ITM Solucin GmbH
- Intervention
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT(drug)
- Enrollment
- 259 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- Stanford Cancer Center, Palo Alto, California, United States
- University of Colorado Hospital, Nuclear Medicine, Aurora, Colorado, United States
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic - Rochester, Department of Oncology, Rochester, Minnesota, United States
- Washington University Alvin J. Siteman Cancer Center, St Louis, Missouri, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- ICAHN School of Medicine at Mount Sinai, Tish Cancer Institute, New York, New York, United States
- Duke University School of Medicine, Duke Cancer Institute, Durham, North Carolina, United States
- Oregon Health and Science University, Portland, Oregon, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- Texas Oncology, Dallas, Texas, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
- Royal North Shore Hospital, St Leonards, New South Wales, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04919226 on ClinicalTrials.govOther trials for Functioning neuroendocrine tumor of pancreas
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT03375320Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsNational Cancer Institute (NCI)
- RECRUITINGNCT00830557Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersMayo Clinic
See all trials for Functioning neuroendocrine tumor of pancreas →